Clinical Trial Update: A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102) [Phase 3]

View source ↗

Summary

Phase 3 long-term study of ERN/LRPT (extended-release niacin/laropiprant) for dyslipidemia completed with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• ERN/LRPT (Extended Release Niacin/Laropiprant) (Extended-release niacin / laropiprant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Dyslipidemia | Phase 3 | Status: COMPLETED | Results posted: 2012-02-17